| Range: | 2.69-12.89 | Vol Avg: | 32562 | Last Div: | 0 | Changes: | 0.29 |
| Beta: | 0.88 | Cap: | 0.24B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Jun 24 2014 | Empoloyees: | 16 | ||
| CUSIP: | 08205P100 | CIK: | 0001808898 | ISIN: | US08205P2092 | Country: | US |
| CEO: | Dr. Jerel A. Banks M.D., Ph.D. | Website: | https://benitec.com | ||||
BNTC 0.00 Stock Price Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow